Sanofi Pasteur, the vaccines division of the Sanofi-Aventis Group, received approval from the FDA for the expanded use of meningococcal conjugate vaccine Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine), in infants and children 9 to 23 months of age. The approval was based on results from a Phase II trial and three Phase III trials in more than 3,300 infants that received Menactra vaccine using a two-dose schedule. Results showed that two ...